

# 2015-2016 Synagis® Seasonal Respiratory Syncytial Virus Enrollment Form



Fax Referral To: 877-552-2907  
 Phone: 888-345-1678  
 Email Referral To: customerservicefax@caremark.com

## 6 Simple steps to submitting a referral

### 1 PATIENT INFORMATION

(Complete the following or include demographic sheet)

Patient Name: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Primary Phone: \_\_\_\_\_  Home  Cell  Work  
 Alternate Phone: \_\_\_\_\_  Home  Cell  Work  
 DOB: \_\_\_\_\_ Gender:  Male  Female  
 E-mail: \_\_\_\_\_  
 Last Four of SS #: \_\_\_\_\_ Primary Language: \_\_\_\_\_  
 Parent/Guardian Name: \_\_\_\_\_

### 2 PRESCRIBER INFORMATION

Prescriber's Name: \_\_\_\_\_  
 State License #: \_\_\_\_\_ NPI #: \_\_\_\_\_  
 DEA #: \_\_\_\_\_  
 Group or Hospital: \_\_\_\_\_  
 Address: \_\_\_\_\_  
 City, State, Zip: \_\_\_\_\_  
 Phone: \_\_\_\_\_ Fax: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_ Phone: \_\_\_\_\_

### 3 INSURANCE INFORMATION Please fax a copy of prescription and insurance cards with this form, if available (front and back).

**Prescription Card:** Name of Insurer: \_\_\_\_\_ ID#: \_\_\_\_\_ BIN: \_\_\_\_\_ PCN: \_\_\_\_\_ Group: \_\_\_\_\_  
**Prescription Insurance:** Subscriber: \_\_\_\_\_ ID#: \_\_\_\_\_ Name of Insurer: \_\_\_\_\_ Phone: \_\_\_\_\_  
**Secondary Insurance:** Subscriber: \_\_\_\_\_ ID#: \_\_\_\_\_ Name of Insurer: \_\_\_\_\_ Phone: \_\_\_\_\_

### 4 DIAGNOSIS AND CLINICAL INFORMATION

Needs by Date: \_\_\_\_\_ Expected date of first injection: \_\_\_\_\_ Ship to:  Prescriber Office  Patient Home  Other: \_\_\_\_\_  
 Yes, CVS Caremark is to coordinate home health nurse visit for injection  No coordination If yes, agency of choice: \_\_\_\_\_

#### Diagnosis (ICD-9 or ICD-10)

< 24 wks of gestation (765.21)  24 wks of gestation (765.22)  25-26 wks of gestation (765.23)  27-28 wks of gestation (765.24)  
 29-30 wks of gestation (765.25)  31-32 wks of gestation (765.26)  33-34 wks of gestation (765.27)  35-36 wks of gestation (765.28)  
 37 wks + of gestation (765.29)  Congenital Heart Disease (Specify ICD-9): \_\_\_\_\_  Other: \_\_\_\_\_  
 Chronic Respiratory Disease arising in the perinatal period (CLD) (770.7)  Congenital Abnormality of Respiratory System (748.3-748.4)

Patient's gestational age (Required) weeks days Current weight: g/kg/lbs Date recorded: / /  
 Multiple births:  No  Yes Enter names of Synagis candidates (submit separate enrollment forms): \_\_\_\_\_  
 NICU history:  No  Yes If yes, NICU name & include NICU summary: \_\_\_\_\_  
 Allergies: \_\_\_\_\_ Medical conditions not listed below: \_\_\_\_\_

#### Clinical Conditions

2014 AAP Committee on Infectious Disease and Bronchiolitis Guidelines

#### Chronic Lung Disease (CLD)

\*CLD of prematurity defined as gestational age  $\leq$  31 weeks, 6 days, AND requirement for 21% oxygen for at least the first 28 days after birth  
 < 12 months of age w CLD \*  
 12-24 months of age w CLD \* AND continues to require medical support\* during the 6-month period before second RSV season AND  
 Supplemental oxygen (dates) \_\_\_\_\_  
 Diuretic therapy (drugs/dates) \_\_\_\_\_  
 Chronic corticosteroids (drugs/date) \_\_\_\_\_  
 Bronchodilators (drugs/dates) \_\_\_\_\_

#### Congenital Heart Disease (CHD)

< 12 months of age at start of season with hemodynamically significant CHD such as:  
 Acyanotic heart disease and receiving medication to control congestive heart failure and surgery to correct (Meds/dates) \_\_\_\_\_ (Surgery date) \_\_\_\_\_  
 Moderate to severe pulmonary hypertension  
 Other: describe \_\_\_\_\_  
 < 24 months of age undergoing cardiac transplantation during the RSV season (date) \_\_\_\_\_

#### Airway/Neuromuscular Conditions

< 12 months of age at start of season and compromised handling of secretions AND due to:  
 Significant abnormality of the airway (attach clinical notes)  
 Neuromuscular condition (attach clinical notes)

#### Prematurity

$\leq$  GA 28 wks, 6 days AND < 12 months at start of season

#### Other medical history or conditions

Other medical history (describe) \_\_\_\_\_

### 5 PRESCRIPTION INFORMATION

MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Synagis® (palivizumab) and ancillary supplies*	<input type="checkbox"/> 50 and/or 100 mg vials	<input type="checkbox"/> Inject 15 mg/kg IM one time per month <input type="checkbox"/> Other: _____	QS to achieve 15mg/kg dose	
<input type="checkbox"/> Epinephrine and ancillary supplies **	1:1000 amp	Inject 0.01 mg/kg subcutaneously as directed for anaphylaxis		

\*This prescription also covers ancillary supplies (syringes, needles, etc.) for administration as needed.

\*\*When required for home/injection clinic administration

Patient is interested in patient support programs

STAMP SIGNATURE NOT ALLOWED

6

X \_\_\_\_\_ X \_\_\_\_\_  
 DISPENSE AS WRITTEN (Date) PRODUCT SUBSTITUTION PERMITTED (Date)